secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2023-03-20T23:59:59+00:00
Accession:  0001193125-23-074426
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences presents one-year IGNITE DMD data; SGT-001 program concluded
------------------------------------------------------------------------------

- One-year data: mean 69.8% normal dystrophin by Western blot in 2E14 vg/kg cohort (Pt.5 at 18 months).
- Motor function: 6MWT and NSAA showed positive mean change from baseline at 1 year.
- Pulmonary function: FVC % predicted and FEV1 % predicted improved from baseline.
- Safety: 2/9 SAEs related to SGT-001 (thrombocytopenia, hepatotoxicity, systemic inflammatory response).
- SGT-001 program concluded; next-gen SGT-003 with novel capsid in IND-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312523074426/0001193125-23-074426-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312523074426/d487716d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-074426

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer